Healthmine‘s EVP of Consulting Melissa Smith recently shared how health plans can put measures in place to advance health equity. The article responds to the recent release of the 2022 Medicare Advantage Readiness Checklist, which includes a front-page reminder to MA plans of Executive Order 13985 (Advancing Racial Equity and Support for Underserved Communities Through the Federal Government). Learn Melissa’s take on what this means for plans, as well as four next steps to take.
To read more, click here.
Seven Bridges this week announced that ARIA, the company’s powerful cloud-based solution to help researchers integrate and analyze complex sets of genomic data at the population level, is now available broadly to North American and European biopharmaceutical companies that are looking to advance drug development. Since the initial announcement of ARIA in February 2020, Seven Bridges has partnered with research institutes and commercial agencies, using ARIA to drive insights from data at the million-participants scale and above. Results from these pilot programs have demonstrated that ARIA can accelerate the speed to insights through a broad set of dynamic capabilities, including support for a wide variety of rich data models and integrations and user-configurable dashboards, as well as the reduction of query times. Today, Seven Bridges is pleased to offer ARIA for biopharmaceutical and clinical researchers to improve and accelerate discovery of outcomes using clinical and genomics data at population scale.
“ARIA provides a comprehensive solution to meet the challenges of the million genome era to improve the precision, breadth and rate of discovery of meaningful connections between genetics and health outcomes,” said Brandi Davis-Dusenbery, chief scientific officer, Seven Bridges. “ARIA’s customizable modules provide the flexibility to adapt to the unique challenges of your organization, your data and your science today — and tomorrow.”
Redi.Health, a company founded by staff from CoverMyMeds and Beam Dental, have raised seed funding to develop its mobile software, according to Columbus Business First. A regulatory filing revealed that it raised $1.3 million , but did not reflect the final amount.
Cleveland, Ohio-based Mutual Capital Partners led the round with additional investment from M25, Rev1 Ventures and Plug and Play. The funds will be used to broaden the development and availability of its technology, which is designed to improve daily health management for patients struggling to manage three or more chronic conditions.
Redi.Health combines health management and partnered pharmaceutical manufacturer support into a tool to deliver a patient-centric platform that helps people improve their adherence as well as their quality of life.
“By providing a contemporary pathway for pharmaceutical companies, hubs, and other partners to support and engage patients digitally, Redi.Health aims to bridge the technology gap of Pharma and Patient Support so patients can achieve their best outcome,” said Luke Buchanan, co-founder and CEO of Redi.Health. “With this funding from leaders in Ohio and beyond, we’re poised to accelerate our commercialization of this very important technology.”
To read more, click here.
Xealth, a digital health company that spun out from Providence St. Joseph Health in 2017, added Trinity Health as an investor in its $25 million Series B round. closed a $10 million Series B round. Trinity is one of 15 health systems that has invested in the business.
The company provides centralized integration, prescribing, monitoring and governance for digital health tools from current clinician workflows. It aims to substantially reduce integration and deployment costs, and boost patient engagement with digital tools. It has been deployed for maternity, diabetes, behavioral health, heart disease, kidney disease, advance directives, infectious disease, surgery preparation, among other areas.
Additional investors include Cerner, LRV Health, Threshold Ventures, McKesson Ventures, Novartis, Philips, and ResMed.
To read more, click here.
Jefferson Health, a Philadelphia health system, and General Catalyst, a venture capital company that invests in seed stage and growth stage companies, have developed a formal collaboration designed to provide novel technology to support the health system accomplish strategic priorities, such as modernizing its technology platform and diversifying revenue streams.
The partnership will include General Catalyst portfolio companies, including Commure and Tendo, and may expand to include others.
Dr. Stephen Klasko, who is retiring as CEO of Jefferson Health at the end of the year, said in a press release: “Our partnership with General Catalyst and its companies enables us all to work towards outcomes none of us could achieve on our own: better patient experiences, reduced costs, and expanded access to quality care while solving for the proliferation of siloed, disconnected technology solutions.”
For General Catalyst, the deal reimagines the role of a venture capital firm — going beyond the traditional focus of just funding companies to thinking about how to build, focus and federate them.
To read more, click here.
Picture: akindo, Getty Images
